Dataset Information

Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL ^TM).

ABSTRACT: Resveratrol exhibits a wide range of biological properties, including anti-glycation, antioxidant, anti-inflammation, neuroprotective (including against advanced dementia and Alzheimer's disease), anti-cancer, and anti-aging activity in experimental models (Galiniak et al., Acta Biochim Pol 66:13-21, 2019). Unfortunately, this compound exhibits low bioavailability and solubility (Galiniak et al., Acta Biochim Pol 66:13-21, 2019), requiring large doses that can cause nausea and GI distress. JOTROL^TM is a micellar 10% resveratrol solubilization formulation that is thought to increase bioavailability of resveratrol via lymphatic system absorption. Jupiter Neurosciences (formerly Jupiter Orphan Therapeutics; "Jupiter") is pursuing the use of resveratrol in mucopolysaccharidosis type 1 (MPS 1), Friedreich's ataxia, and Alzheimer's disease/mild cognitive impairment. This paper describes a first in human study (FIH) to evaluate the bioavailability of resveratrol after ascending, single oral doses up to 700 mg resveratrol as JOTROL^TM. After a single 500 mg dose of JOTROL^TM, a Cmax of 455 ng/mL was observed, vs. 85 ng/mL Cmax after a 1 g encapsulated dose (Turner et al., Neurology 85:1383-91, 2015) and 1942 ng/mL after a 2.5 g micronized dose (Howells et al., Cancer Prev Res (Phila) 4:1419-1425, 2011). In this study, resveratrol exposures (AUCs and Cmax) increased with increasing doses. This increase appears to be higher than dose-proportional for AUC_0-t and Cmax. Resveratrol and its three major conjugates accounted for 40 to 55% of the dose in urine, consistent with a high extent of absorption, but < 1% of drug-related material was intact relative to key metabolites in plasma and urine. Studies in Alzheimer's patients and in MPS 1 are currently in development to test the effect this improved bioavailability has on those patient populations (Clintrials.gov, NCT04668274, 12/16/2020, https://clinicaltrials.gov/ct2/show/NCT04668274).

Supplementary information

The online version contains supplementary material available at 10.1186/s41120-022-00058-1.

SUBMITTER: Kemper C

PROVIDER: S-EPMC9243782 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:BackgroundLotilaner is a new member of the isoxazoline class for treatment of flea and tick infestations in cats. This laboratory study with lotilaner vanilla-yeast flavoured chewable tablets (CredelioTM, Elanco) investigated the safety in healthy kittens starting at 8 weeks of age in a randomized, blinded, parallel-group design. Lotilaner tablets were given orally once a month over eight months at one, three and five times the upper level of the maximum recommended dose range (26 mg/kg).MethodsThe safety of lotilaner flavoured chewable tablets was assessed in healthy kittens when administered orally every 4 weeks for 8 months at the highest recommended dose rates, i.e. 1× (26 mg/kg) and at elevated dose rates, i.e. 3× (78 mg/kg) and 5× (130 mg/kg). Sixteen male and 16 female healthy 8-week-old kittens, with a mean body weight of 0.79 kg and 0.75 kg, respectively, were randomized to an untreated control group or lotilaner groups at dose rates of 26 mg/kg (1×), 78 mg/kg (3×), or 130 mg/kg (5×) every four weeks over eight months. The control group was sham-dosed. All animals were fed within 30 minutes prior to treatment. Safety assessment included general health observations, detailed clinical observations, complete physical/neurological examinations, including ophthalmological examinations, electrocardiographic (ECG) and clinical pathology evaluations (haematology, clinical chemistry and urinalysis), food and water consumption, body weight, pharmacokinetic blood collections, organ macroscopic and microscopic examinations.ResultsSystemic exposure to lotilaner was confirmed during the course of the study in all treated animals with the exception of the control group. No treatment-related effects were seen on daily clinical observations, food consumption (wet), ophthalmoscopic, physical/neurological and microscopic examinations. Statistically significant differences were recorded in some of the clinical pathology parameters, body weights, food consumption (dry), electrocardiograms, and organ weights, but none of the recorded observations was considered to be of clinical relevance.ConclusionsLotilaner, when administered once monthly over eight months at the highest recommended dose and overdoses of three- and five-fold, to 8-week-old healthy kittens, is well tolerated.

Project description:Seven percent of UK households are estimated to own both a cat and a dog, despite a popular view that the two do not live well together. This is the first study to evaluate the effects of pheromone products Feliway FriendsTM and AdaptilTM on cat-dog interactions, in homes where owners perceived the potential for improvement in the relationship between their cat and dog. A blinded parallel randomized trial design over a 6-week period was used to evaluate the effect of each of the two products, with 17 participants in each group completing the trial. Owners reported weekly on the frequency of 10 specific undesirable interactions and seven specific desirable interactions. Total undesirable and desirable interaction scores both showed significant linear contrasts over time (undesirable score decreased; desirable score increased). Undesirable interaction scores were significantly lower (with a very large effect size) during treatment compared with baseline. There were no significant differences between the two pheromone products in relation to these outcome measures. AdaptilTM and Feliway FriendsTM were both associated with a significant decrease in: dog chasing cat/cat runs away; cat hiding from dog; cat/dog staring at the other; and dog barking at cat. With AdaptilTM a significant increase was also seen in: friendly greeting and times spent relaxed in the same room. From baseline (Week 2) to the end of the study (Week 6) there was a significant improvement in owners' perception of dog relaxation in those participants who received AdaptilTM and of cat relaxation in those participants who received Feliway FriendsTM. Similarity in the core chemical structure of the appeasing pheromones might explain the main effects, whilst different species-specific additions may explain the product-appropriate species-specific increases in relaxation scores. Specific behavioral improvements seen with AdaptilTM may reflect a greater calming of dogs in this group, reducing their interest in seeking interaction with cats in the same home and the tension in the cat as a result. In conclusion, both products appear to improve the cat-dog relationship and it would be beneficial to further study their use in combination and against placebo. If selecting one product AdaptilTM may be preferable, unless there is a particular need to increase the cat's relaxation.

Project description:Background: Information technology (IT) is an industry related to the production of computers, information processing, and telecommunications. Such industries heavily rely on the knowledge and solutions provided by IT specialists. Previous reports found that the subjective stress scores were higher in IT specialists who developed diabetes, hypertension, and depression. Specific probiotics, known as psychobiotics, may alleviate stress and mood symptoms. This study aimed to examine whether an 8-week intervention of a novel psychobiotic, Lactobacillus plantarum PS128TM (PS128TM), improved self-perceived stress and mood symptoms among high-stress IT specialists. Methods: This open-label, single-arm, baseline-controlled study included IT specialists from a large IT company in Northern Taiwan. Participants with a Perceived Stress Scale (PSS) 10-item version score of 27 or higher were included. Participants were asked to take two capsules containing PS128TM powder, equivalent to 20 billion colony-forming units, daily. Self-report measures, such as the Job Stress Scale, Visual Analog Scale of Stress, the Insomnia Severity Index, the State and Trait Anxiety Index, the Questionnaire for Emotional Trait and State, the Patient Health Questionnaire, the Quality of Life Enjoyment and Satisfaction Questionnaire, and Gastrointestinal Severity Index were compared at baseline and at the end of the trial period. The primary outcome was a 20% reduction in the PSS score at endpoint. Objective measures included salivary levels of stress biomarkers, including cortisol, α-amylase, immunoglobulin A, lactoferrin, and lysozymes, as well as results of the Test of Attentional Performance. Results: Of the 90 eligible IT specialists, 36 met the inclusion criteria. After the 8-week trial period, significant improvements in self-perceived stress, overall job stress, job burden, cortisol level, general or psychological health, anxiety, depression, sleep disturbances, quality of life, and both positive and negative emotions were found. Conclusion: Our results suggest that PS128TM has the distinct advantage of providing stress relief and can improve mental health for people with a high-stress job. Future placebo-controlled studies are warranted to explore the effect and underlying mechanisms of action of PS128TM. Clinical Trial Registration: https://clinicaltrials.gov/ (identifier: NCT04452253-sub-project 2).

Dataset Information

Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL ^TM).

Supplementary information

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL TM).

Supplementary information

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL ^TM).